Fat-Dissolving Shot CBL-514 Cuts Visceral Fat 12% in Early Trials

The experimental injection CBL-514, which triggers fat-cell apoptosis, reduced visceral fat by an average 12.01% in two phase 2 trials, while placebo recipients gained 5.68%. Injection-site reactions were mostly mild and temporary, with no serious adverse events reported.

• Visceral fat fell 12.01% four weeks after treatment vs a 5.68% rise on placebo
• Between-group difference in fat volume change reached 22.21 percentage points
• 69.6% of treated participants lost at least 150 ml of subcutaneous fat vs 0% on placebo
• Doses up to 600 mg every three weeks; phase 3 underway with first results due late 2027